Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-08-15
2009-06-09
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254090, C514S323000, C514S339000, C544S362000, C544S373000, C546S201000, C546S278100
Reexamination Certificate
active
07544685
ABSTRACT:
The invention relates to compounds of the formula Iwherein the variables are as defined in the claims. The compounds are useful in the treatment of a disease where a D4 receptor and/or a 5-HT2Areceptor is implicated.
REFERENCES:
patent: 5700802 (1997-12-01), Curtis et al.
patent: 6313297 (2001-11-01), Herwig et al.
patent: 0 624 584 (1998-08-01), None
patent: WO 94/20497 (1994-09-01), None
patent: WO 94/22839 (1994-10-01), None
patent: 98/28293 (1998-07-01), None
patent: WO 98/28293 (1998-07-01), None
patent: WO 99/36412 (1999-07-01), None
patent: WO 99/37304 (1999-07-01), None
Jones et al. Pharmacology, Biochemistry and Behavior, vol. 71,p. 555-568 (2002).
Robichaud et al. in Annual Reports in Medicinal Chemistry, vol. 36, p. 11-20 (2000).
Truffinet et al. Am.J.Psychiatry, vol. 156, p. 419-425 (1999).
Arora et al. Bioorganic & Medicinal Chemistry Letters, vol. 15, p. 5253-5256 (2005).
Mansbach, R.S., et al., “Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade or prepulse inhibition”, Psychopharmacology, 1998, 194-200, vol. 135.
McCracken, JT, et al., “Evidence for linkage of a tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD)”, Molecular Psychiatry, 2000, 531-536, vol. 5.
Meert, T.F. and Janssen, P.A.J., “Psychopharmacology of Ritanserin: Comparison With Chlordiazepoxide”, Drug Dev. Res., 1989, 119-144, vol. 18.
Obach, R.S., et al., “The Prediction of Human Pharmacokinetic Parameters from Preclinical and In Vitro Metabolism Data”, JPET, 1997, 46-58, vol. 283, No. 1.
Sanner, M. A., “Selective dopamine D4 receptor antagonists”, Exp. Opin. Ther. Patents, 1998, 383-393, vol. 8, No. 4.
Van Tol H.H.M., et al., “Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine”, Nature, Apr. 18, 1991, 610-614, vol. 350.
Zhang, K., et al., “Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions”, Psychopharmacology, 2002, 100-106, vol. 161.
Benet, L.Z., “The Role of Pharmacokinetics in the Drug Development Process”, Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development, Edited by A. Yacobi, et al., 1993, pp. 115-123, Plenum Press, New York.
Carlsson, A., “Editorial Review: Focusing on dopaminergic stablizers and 5-HT2A receptor antagonists”, Current Opinions in CPNS Investigational Drugs, 2000, 22-24, vol. 2, No. 1.
Colpaert, F.C., et al., “Behavioral and 5-HT antagonist effects of ritanserin: A pure and selective antagonist of LSD discrimination in rat”, Psychopharmacology, 1985, 45-54, vol. 86.
Connor, D.F., et al., “Biogenic amines and the psychopharmacology of aggression”, Exp. Opin. Ther. Patents, 1998, 349-359, vol. 8, No. 4.
Gazi, L., et al., “The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor”, Br. J. of Pharmacology, 1998, 889-896, vol. 124.
Gazi, L., et al., “Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells”, Br. J. of Pharmacology, 1999, 613-620, vol. 128.
Gelders, Y. G., “Thymosthenic Agents, A Novel Approach in the Treatment of Schizophrenia”, Br. J. of Psychiatry, 1989, 33-36, vol. 155 (suppl. 5).
Hadley, M. S., “D4 Receptors and Their Antagonists”, Medicinal Research Reviews, 1996, 507-526, vol. 16, No. 6.
Jentsch, J. D., “Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys”, Psychopharmacology, 1999, 78-84, vol. 142.
Leysen, D., et al., “5-HT2 Antagonists: a Concept for the Treatment of Schizophrenia”, Current Pharmaceutical Design, 1997, 367-390, vol. 3.
Roth, Bryan, L., et al., “Magic Shotguns Versus Magic Bullets: Selectively Non-Selective Drugs for Mood Disorders and Schizophrenia”, Nature Reviews Drug Discovery, Apr. 2004, 353-359, vol. 3.
Bang-Andersen Benny
Larsen Krestian
Mørk Niels
Bernhardt Emily
Buck Margaret M.
H. Lundbeck A/S
Kalinchak Stephen G.
LandOfFree
2,3-dihydroindole compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,3-dihydroindole compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,3-dihydroindole compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4110264